HYTN Welcomes U.S. Recommendation to Reclassify Cannabis, Foresees Growth
VANCOUVER, British Columbia, May 01, 2024 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN “HYTN” or “The Company”), a leader in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds including cannabis, applauds the recent formal recommendation by the U.S. Justice Department, endorsed by the Drug Enforcement Agency (DEA), to reclassify cannabis from a Schedule I to a Schedule III controlled substance.
Related news for (HYTNF)
- HYTN Completes Acquisition of Prism Scientific Labs, Enhancing Psychedelic Compound Manufacturing Capabilities
- HYTN Awarded Drug Establishment License from Health Canada, Expanding GMP Capabilities
- HYTN Innovates GMP Stability Programs, Sets Industry Benchmark
- HYTN Welcomes Health Canada for Audit to Enhance GMP Capabilities